Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity

Günay, Murat; Tüten, Abdülhamit; Sancak, Selim; Çelik, Gökhan; Bardak, Handan; Dinçer, Emre; Karatekın, Güner; Erdoğan, Gürkan; Bardak, Yavuz

doi:10.1159/000443208

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced peak systolic and mean blood flow velocities in the ophthalmic artery after intravitreal bevacizumab have been reported in 15 infants. 23 In contrast, treatment with intravitreal aflibercept was associated with a slight decline of CRA peak systolic velocity, a marked decline in CRA end-diastolic flow velocity, and an increase in CRA resistance index in 15 preterm infants with severe ROP. 5 Using laser speckle flowgraphy imaging, a technique that requires sedation and pharmacological mydriasis, intravitreal bevacizumab was found to result in decreased venous dilation, arterial tortuosity, and overall ocular blood flow in four preterm infants from Japan.…”

Section: Discussionmentioning

confidence: 84%

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Mohr

Fischer

Czernik

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

Background/Objectives Progression of retinopathy of prematurity (ROP) is associated with increased retinal blood flow velocities. We investigated changes of central retinal arterial and venous blood flow after intravitreal administration of bevacizumab. Subjects/Methods Prospective observational study using serial ultrasound Doppler imaging in preterm infants with bevacizumab-treated ROP. Eyes were examined 1 [0–2] days before injection (median [interquartile range]), and at three time points after injection (1 [1–2] days, 6 [3–8] days, and 17 [9–28] days). Preterm infants with ROP stage 2 displaying spontaneous regression served as controls. Results In 21 eyes of 12 infants with bevacizumab-treated ROP, peak arterial systolic velocity declined from 13.6 [11.0-16.3] cm/s prior to intravitreal bevacizumab to 11.2 [9.4–13.9] cm/s, 10.6 [9.2–13.3] cm/s and 9.3 [8.2–11.0] cm/s at discharge ( p = .002). There was also a decline of the arterial velocity time integral (from 3.1 [2.3–3.9] cm to 2.9 [2.4–3.5], 2.7 [2.3–3.2] cm and 2.2 [2.0–2.7], p = .021) and mean velocity in the central retinal vein (from 4.5 [3.6–5.8] cm/s to 3.7 [2.6–4.1] cm/s, 3.5 [3.0–4.3] cm/s, and 3.2 [2.8–4.6] cm/s, p = .012). Arterial end-diastolic velocity and resistance index remained unchanged. Blood flow velocities in bevacizumab-treated eyes examined before injection were significantly higher than those measured in untreated eyes that ultimately showed spontaneous regression of ROP. Sequential examinations in these controls did not reveal any declines of retinal blood flow velocities. Conclusion Increased retinal arterial and venous blood flow velocities in infants with threshold ROP decline following intravitreal bevacizumab injection.

show abstract

Section: Discussionmentioning

confidence: 84%

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Mohr

Fischer

Czernik

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Effects of anti-VEGF agents applied intravitreally on ocular hemodynamics were previously identified using CDI (16)(17)(18)20). Toklu et al (16) have reported on the blood flow analysis of CRA in patients with age-related macular degeneration (AMD) after injection of bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

“…Günay et al (18) showed the effect of IVB on retrobulbar hemodynamic parameters in infants with ROP. There was a Values are means ± SD.…”

Section: Discussionmentioning

confidence: 99%

Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity

Sukgen

Söker

Koçluk

et al. 2017

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Gunay et al [9] recently reported the changes in blood flow from before to after an intravitreal bevacizumab treatment for ROP; they observed that the blood flow velocity in the ophthalmic artery had decreased. There are differences in treatment methods, but similar results were obtained in this study.…”

Section: Discussionmentioning

confidence: 99%

A Change in Ocular Circulation after Photocoagulation for Retinopathy of Prematurity in a Neonate

Matsumoto

Itokawa

Shiba

et al. 2017

Case Rep Ophthalmol

View full text Add to dashboard Cite

Background: The dilation of veins and tortuosity of arteries that occur in retinopathy of prematurity (ROP) are improved by therapy, and thus posttherapy changes in ocular circulation are also conceivable. We report a case of ROP in which we were able to measure the ocular circulation before and after photocoagulation therapy, using a laser speckle flowgraphy (LSFG) system that is modified for neonates. Case Report: A female infant was born at 25 weeks’ gestation with a birth weight of 808 g. We performed photocoagulation in both eyes at age 15 weeks, and we measured the ocular circulation with the “LSFG-baby” system before and at 12 weeks after the photocoagulation treatment. We also measured the mean blur rate (MBR) in the optic nerve head (ONH) and the relative flow volume (RFV) in the retinal vessels, and we examined the change rates from before to after treatment. The changing rate of the MBR-A (the mean of all values) in the ONH in the right and left eyes was 76.5 and 98.5%, respectively. The vascular RFV in the severe dilation and tortuosity quadrant also tended to decrease. Conclusions: Photocoagulation improved the dilation of veins and tortuosity of arteries and reduced the ocular blood flow in this neonate with ROP. The LSFG-baby system effectively and directly revealed the optic nerve and retinal blood vessels.

show abstract

Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity

Cited by 7 publications

References 27 publications

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab

Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity

A Change in Ocular Circulation after Photocoagulation for Retinopathy of Prematurity in a Neonate

Contact Info

Product

Resources

About